The Hydration Pharmaceuticals Company Limited ACN 620 385 677 PROSPECTUS Non-renounceable pro-rata entitlement offer of 2 New Shares for every 3 Shares held on the Record Date at an issue price of $0.004 per New Share, together with 1 free-attaching New Option for every 2 New Shares subscribed for...
Prospectus - Non Renounceable Rights Issue
Filed with ASX ·
6ix is reading this filing.
Hydration Pharmaceuticals Company Limited on 6ix
Earlier from Hydration Pharmaceuticals
- Rights Issue and UMP Share Sale Facility
- July and August 2026 Trading Update
- Appendix 4D and FY26 Half Year Financial Report
- Q2 FY26 Quarterly Activities Report (App 4C)
- Capital raising, board renewal and management changes
Follow Hydration Pharmaceuticals into a list and get an email when it puts out news.
Follow Hydration Pharmaceuticals